Cash Flow Statement
Quarterly Data
The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.
The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
The financial trajectory from early 2021 through late 2026 is characterized by strong operational cash generation offset by an aggressive strategic acquisition program and a consistent commitment to shareholder returns. While net income exhibits significant volatility, primarily due to large non-cash charges and R&D asset acquisitions, the net cash provided by operating activities remains generally robust, providing the primary funding source for investment and financing activities.
- Operating Cash Flow Dynamics
- Net income from continuing operations shows high variability, with notable contractions in June 2023, December 2023, March 2026, and June 2026. These fluctuations are largely attributed to substantial charges for research and development asset acquisitions, most notably a 10.2 billion USD charge in June 2023 and an 8.5 billion USD charge in March 2026. Despite these accounting headwinds, net cash provided by operating activities frequently exceeds net income, supported by consistent amortization and depreciation expenses, which trended upward toward 2026. Operating cash flow peaked at 9.29 billion USD in September 2024, demonstrating a strong underlying capacity to generate liquidity from core business operations.
- Investment and Acquisition Strategy
- Investing activities are dominated by a series of high-value acquisitions. Major capital outflows include the acquisition of Acceleron Pharma (11.17 billion USD in December 2021), Prometheus Biosciences (10.7 billion USD in June 2023), Verona Pharma (10.04 billion USD in December 2025), and Cidara Therapeutics (8.78 billion USD in March 2026). Capital expenditures have remained relatively stable, typically fluctuating between 700 million USD and 1.3 billion USD per quarter. This pattern indicates a dual-track investment strategy: maintaining existing infrastructure through steady CapEx while aggressively expanding the product pipeline through external acquisitions.
- Financing and Shareholder Returns
- A disciplined approach to shareholder distributions is evident through steadily increasing dividend payments, which grew from approximately 1.6 billion USD per quarter in 2021 to over 2 billion USD per quarter by 2026. Share buybacks through treasury stock purchases also accelerated over the period, with quarterly outflows increasing from a few hundred million USD in 2021 to consistently exceeding 1 billion USD in several quarters between 2024 and 2026. These activities are funded by a combination of operating cash and periodic debt issuances, such as the 7.9 billion USD issuance in December 2021 and March 2026.
- Liquidity and Net Cash Positioning
- The net change in cash is subject to extreme quarterly swings, reflecting the timing of multi-billion dollar acquisition payments and debt procurement. A significant liquidity event occurred in June 2021 with a 9 billion USD distribution from Organon & Co. The overall liquidity position is managed through a cycle of utilizing operating cash for dividends and CapEx, while leveraging the debt market to finance strategic mergers and acquisitions, as seen in the repeated pattern of large debt proceeds coinciding with major acquisition outflows.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?